GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Total Payout Yield %

BCAX (Bicara Therapeutics) Total Payout Yield % : 0.00 (As of Mar. 03, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Bicara Therapeutics's current Total Payout Yield % is 0.00%.


Bicara Therapeutics Total Payout Yield % Historical Data

The historical data trend for Bicara Therapeutics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Total Payout Yield % Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23
Total Payout Yield %
- -

Bicara Therapeutics Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Total Payout Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Bicara Therapeutics's Total Payout Yield %

For the Biotechnology subindustry, Bicara Therapeutics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicara Therapeutics's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Total Payout Yield % falls into.



Bicara Therapeutics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Bicara Therapeutics's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 0 + 0) / 0
=N/A%

Bicara Therapeutics's annualized Total Payout Yield % for the quarter that ended in Sep. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 1385.8227
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bicara Therapeutics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Bicara Therapeutics Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicara Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Website
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.